Blockade of PD-1 and PD-L1 molecules has been recognized as a promising approach for cancer immunotherapy9; however, to date, the efficacy of checkpoint inhibitors in myeloproliferative diseases is not clear. The gene discussed is CD274; the disease is myeloproliferative disorder.